Estimating Clinical Outcome of HPV Induced Cervical Lesions by Combination of Capsid Protein L1 and p16INK4a Protein Detection by Ines Krivak Bolanča et al.
Coll. Antropol. 34 (2010) 1: 31–36
Original scientific paper
Estimating Clinical Outcome of HPV Induced
Cervical Lesions by Combination of Capsid
Protein L1 and p16INK4a Protein Detection
Ines Krivak Bolan~a1, Karmela [entija1, Suzana Kataleni} Simon1, Vlastimir Kukura2,4
and Jasmina Vrane{3,4
1 Laboratory for Cytology and Clinical Genetic, Department of Gynaecology & Obstetrics, University Hospital »Merkur«, Zagreb,
Croatia
2 Department of Gynaecology & Obstetrics, University Hospital »Merkur«, Zagreb, Croatia
3 Institute of Public Health »Dr. Andrija [tampar«, Zagreb, Croatia
4 University of Zagreb, School of Medicine, Zagreb, Croatia
A B S T R A C T
The aim of this study was to investigate whether is possible to predict clinical outcome of cervical lesion by immu-
noassaying performed on cervical smears. During the two year study period the cervical smears of 81 patients were col-
lected. All patients were tested for human papillomavirus (HPV) infections using Amplycor HPV test. Sixty-six of them
were tested as positive for high risk types (hrHPV) and squamous intraepithelial lesion, and in those patients repeated
cervical smears were taken every six months. The rest were hrHPV negative patients with normal smears which were
used as a negative control in immunoassays with HPV L1 and p16INK4a antibodies. The results of p16INK4a staining in 66
hrHPV positive patients showed impairment of the cervical lesion in 22 (33.3%) and unchanged cytological finding in 21
(31.9%) p16INK4a positive patients, respectively, while improving of cytological finding was seen only in three (4.5%)
p16INK4a positive patients. On the contrary, impairment of cytological finding was not seen in p16INK4a negative patients,
while in 17 out of 20 patients from that group improving or normalisation of cytological finding were detected (p<0.01).
Correlation between L1/p16 pattern and cytological finding showed that only in L1–/p16+ cervical lesions was detected
impairment of cytological finding during the study period. In L1+/p16+ group the cytological finding was the same
during the follow up in all 11 patients, while in L1+/p16– group in most patients (9/11) downgrading or normalisation
of Pap test were detected. The usage of p16 and HPV L1 markers can be useful in estimation of biologic potentiality and
clinical outcome of cervical lesions.
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Introduction
Cervical cancer is preventable by early detection of
premalignant lesions. Over the years cervical cytology
has become one of the most valuable methods in cancer
prevention programs. Conventional Pap test is used not
only to distinguish benign from malignant cases but also
as a differential diagnostic method for predicting histo-
logical diagnosis and in that way it interferes with thera-
peutic procedures1. Cervical lesions are associated with
persistent infection with oncogenic types of human pa-
pilloma viruses (HPV). HPV types 16 and 18 cause about
70% of cervical cancers and in more than 99% of cervical
cancers one of 15 high risk HPV types (hrHPV) can be
detected. Detection of hrHPV types is connected with the
need for a larger number of HPV detection probes there-
fore larger expenses. Majority of low grade squamous
intraepithelial lesion (LSIL) and HPV infections are pro-
ne to spontaneous regression especially in younger wo-
men2, and repeated testing can produce unnecessary
anxiety as well as expenses. On the other hand, HPV
testing of the older women can replace frequent Pap
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smears, so postmenopausal women will have longer in-
tervals between smears3. The epidemiological studies
showed that minority of LSIL lesions progressed and
that they were quite often over treated, incurring in-
creased health costs because of the escalated number of
check-ups as well as unnecessary treatments4–5.
Because of subjectivity in Pap smear analyses, results
can vary between investigators. Additional techniques
are needed which are objective and interlaboratory re-
producible in high rates.
Various biomarkers have been evaluated as specific
markers for dysplastic cells on cytological as well as on
histological specimens but with limited clinical use.
Some of those markers in spite of rather high specificity
have lower sensitivity, resulting in some cancer cells or
their precursors being missed in analysis. The value of
expression of p16INK4a (p16) has already been demon-
strated as a surrogate marker for the oncogenic activities
of HPV in the cells of the cervical epithelium3,6. It is a
regular cellular protein which gets overexpressed when
specific viral oncogenes start to interfere with the host’s
cell-cycle regulation, although p16 expression is not ab-
solute specific for hrHPV infection. Expression of p16
underlies a negative feedback control through pRB. In-
hibited function of pRb should result in overexpression
of p16 levels, making it a specific marker for cells with
the expression of HPV oncogenes. HPV infection starts
when a virus enters the epithelial stem cells usually at
the squamo-columnar junction of the uterine cervix.
During this early, so-called productive phase a high level
of early (E2, E4) and late (L1, L2) viral genes occurs
which results with virion particles release. Viral capsid
protein L1 is expressed in that early phase and disap-
pears in the later phases of carcinogenesis, suggesting its
potential role in predicting the outcome of cervical intra-
epithelial lesion4,7–8.
In this study the expression of L1 and p16 in abnor-
mal cervical smears with LSIL (CIN 1) and HSIL (CIN 2)
diagnosis were investigated and compared the results
with the cytological findings of these lesions during the
two years of follow-up. The prognostic relevance in pre-
dicting the clinical outcome of lesions in comparison with
L1/p16 pattern on the basis of repeated cytological smears
is estimated.
Examinees, Materials and Methods
In two year study period the cervical smears from 81
patients were collected in Department of Gynaecology
and Obstetrics at the University Hospital »Merkur«. Pa-
tients were chosen by random selection according to age,
parity and clinical findings. According to cytological diag-
nosis we chose patients with normal Pap smear and
those patients with CIN I (LSIL) or CIN II (HSIL) le-
sions. Patients with CIN III lesions as initial diagnosis
were excluded.
Cervical swabs were taken by a wooden spatula and
cytobrush. After making a smear for cytological examina-
tion which was immediately fixed in 95% ethanol, two
additional smears were made for immunochemical stain-
ing from each patient. Simultaneously, extra smear was
taken for HPV testing.
All patients were tested for hrHPV infection at the
Dr. Andrija Stampar Institute for Public Health by the
polymerase chain reaction based AMPLICOR HPV test
(Roche Molecular System, Roche). Sixty-six patients tes-
ted hrHPV positive, while in 15 patients hrHPV infec-
tion was not confirmed.
Cytology diagnosis was made according to the Be-
thesda classification. In 66 hrHPV positive patients, the
initial cytology result revealed LSIL (CIN 1) in 52, and
high grade lesions (only CIN II) in 14 patients. Patients
without HPV infection, 15 of them had a normal cervical
smear throughout two years, and they represented the
control group in immunostaining procedure.
For immunostaining p16 monoclonal antibody (clone
E6H4, CINTec p16INK4a cytology kit, MTM-laboratories,
Heidelberg, Germany) and a monoclonal antibody L1
(HPV L1, Cytoactive Diagnostics GmBH, Pirmasens,
Germany) were used, and slides were stained according
to the manufacturer’s protocol. Stained smears were
studied under the light microscope and classified as posi-
tive when there was a clear red nuclear staining in just
one cell for HPV L1 assaying (Figures 1, 2), and at least
I. Krivak Bolan~a et al.: HPV and Protein L1 and p16INK4a Protein Detection, Coll. Antropol. 34 (2010) 1: 31–36
32
Fig. 1 and 2. HPVL1 in LSIL (x1000).
1% of stained cells for p16 assaying according to manu-
facturers. Cells treated with the p16 antibody were con-
sidered stained if brownish granules were found in the
nuclei and in the cytoplasms of the cells (Figure 3).
Control cervical smears were taken every six months.
For the study purpose impairment of lesion was defined
as an elevated Pap test resulted in the higher group i.e.,
LSIL to HSIL (CIN 1 to CIN 2 or from CIN 2 to CIN 3)
group, and the stable disease was defined as unchanged
lesion as it was at the initial smear. Improving was de-
fined as normalisation of the Pap test for at least two
consecutive cervical smears within one year period or
down-grading of dysplasia.
In eight patients with an elevated Pap result histo-
logical confirmation of cytological diagnoses was made as
well as treatment according to the guidelines, accepted
by the Croatian Society for Colposcopy and Cervical
Pathology9.
For statistic analysis c2-test was used and p values
<0.01 were defined as significant.
Results
During two years cervical smears of 66 hrHPV posi-
tive and 15 HPV negative patients were analysed. Simul-
taneously with the initial cervical smear, additional smears
were taken and stained with p16 and L1 monoclonal an-
tibodies.
As was expected, the p16INK4a expression was negative
in the 15 hrHPV negative patients, and smears collected
from those patients served as negative control for p16INK4a
immunostaining procedure. The results of p16INK4a stain-
ing in 66 hrHPV positive patients (Table 1) showed im-
pairment of the cervical lesion in 22 (33.3%) and un-
changed cytological finding in 21 (31.9%) p16INK4a posi-
tive patients, respectively, while improving of cytological
I. Krivak Bolan~a et al.: HPV and Protein L1 and p16INK4a Protein Detection, Coll. Antropol. 34 (2010) 1: 31–36
33
Fig. 3. p16INK4a in LSIL (x1000).
TABLE 1
COMPARISON OF P16INK4A POSITIVITY AND CYTOLOGICAL FINDING (N=66)
P16INK4a Impairment Improving Unchanged TOTAL
Positive 22 (33.3%) 3 (4.5%) 21 (31.9%) 46 (69.7%)
Negative – (0.0%) 17 (25.8%) 3 (4.5%) 20 (30.3%)
TOTAL 22 (33.3%) 20 (30.3%) 24 (36.4%) 66 (100.0%)
c2=41.49, p<0.01
TABLE 2
COMPARISON OF L1 POSITIVITY AND CYTOLOGICAL FINDING (N=66)
L1 Impairment Improving Unchanged TOTAL
Positive – (0.0%) 9 (13.6%) 13 (19.7%) 22 (33.3%)
Negative 22 (33.3%) 11 (16.7%) 11 (16.7%) 44 (66.7%)
TOTAL 22 (33.3%) 20 (30.3%) 24 (36.4%) 66 (100.0%)
c2=16.91, p<0.01
TABLE 3
CORRELATION BETWEEN L1/ p16 PATTERN AND CYTOLOGICAL FINDING (N=66)
L1/p16 Impairment Improving Unchanged TOTAL
L1+/p16+ – (0.0%) – (0.0%) 11 (16.7%) 11 (16.7%)
L1+/p16– – (0.0%) 9 (13.7%) 2 (3.0%) 11 (16.7%)
L1–/p16– – (0.0%) 8 (12.1%) 1 (1.5%) 9 (13.6%)
L1–/p16+ 22 (33.3%) 3 (4.6%) 10 (15.1%) 35 (53.0%)
TOTAL 22 (33.3%) 20 (30.4%) 24 (36.3%) 66 (100.0%)
finding was seen only in three (4.5%) p16INK4a positive
patients. On the contrary, impairment of cytological find-
ing was not seen in p16INK4a negative patients, while in
17 out of 20 patients from that group improving or nor-
malisation of cytological finding were detected (c2=
41.49, p<0.01).
The results of HPVL1 staining are summarised in Ta-
ble 2. Overall L1 was expressed in 33.3% cases (22/66).
While not one case showed impairment of cytological
finding when lesion was L1 positive, in half of L1 nega-
tive patients (22/44) impairment of cytological finding
was detected (c2=16.91, p<0.01).
In Table 3 correlation between L1/p16 pattern and cy-
tological finding showed that only in L1 negative/p16
positive cervical lesions was detected impairment of cyto-
logical finding during the study period. Statistically sig-
nificant difference was observed when L1–/p16+ and
L1–/p16– groups were compared (c2=8.9, p<0.01), with
predominant improvement of cytological finding in L1–/
p16– group. In L1+/p16+ group the cytological finding
was the same during the follow up in all 11 patients,
while in L1+/p16– group in most patients (9/11) down-
grading or normalisation of Pap test were detected.
Discussion
Although HPV infection is the most common sexual
transmitted infection, not many women develop cervical
cancer. Cervical cancer can be curable if treated in an
early stage. Early detection of a precancerous lesion is of
importance in reducing mortality. Implementation of the
Pap test as a method of triaging patients in screening
programs all over the world has lead to the reduction of
morbidity and mortality from cervical cancer, especially
in countries with organized screening, and less in coun-
tries with opportunistic screening such as Croatia. De-
spite all advantages, Pap test has some limitations due to
subjectivity of the method, inadequate sample collection
or interpretation errors10–13. All of these contribute to a
false negative result of Pap test up to 50%12. To overcome
these problems new methods and technologies are intro-
duced: like LBC (liquid based cytology) or computerised
image analysis system, but because of higher costs their
implementation into public health screening programs is
limited only to developed countries. Alternative screen-
ing techniques suitable for developing countries are be-
ing investigated in various parts of the world but still not
recommended outside research programs1,9.
It was established that cervical premalignant lesions
and cancer are HPV-induced diseases, and hrHPV nu-
cleic-acid can be detected in almost all HSIL and cervical
cancers. On the other hand, HPV infections exist among
women with no cervical pathology which means that the
positive predictive value of detecting HPV is rather low3.
Until nowadays no worldwide consensus exists with
respect to the choice of the primary screening tests. HPV
tests are more reproducible and sensitive than cervical
cytology but they are also less specific. If HPV test is neg-
ative, a longer screening interval should be considered.
In Europe the standard screening method is still cytol-
ogy-based. However this policy was reviewed and com-
bination of cytology and HPV testing was approved for
primary screening in women over 30 years of age and for
the triage of women with abnormal cytology 15. As von
Doeberlitz suggested3, the optimal screening test would
be the test which can identify true dysplasia in which re-
gression of the lesion is not possible because of the
genomic instability and cellular dysregulation that takes
place after incorporation of HPV oncogenes into the host
genome.
In present study overall L1 positivity was low, only
33.3% among which in 13.6% and 19.7% lesions improve-
ment of cytological finding or unchanged finding were
detected, but in none of L1 positive lesion impairment of
cytological finding was recorded. Relatively low propor-
tion in L1 positive lesion was found in other studies as
well. Griesser et al. reported 34.5% of L1 positive lesions,
similar to Hilfrich and Negri et al., but Rauber et co-wor-
kers reported 61.3% positive nuclear staining4,7,8,16. It
has been found that L1 protein begins to disappear as the
disease progresses. Explanation probably lies in the mat-
uration process of epithelial cells and it’s linkage to the
synthesis of HPV L1 capsid protein in HPV infected cells.
L1 is strongly expressed in the superficial level of epithe-
lium12,17, and since maturation process in dysplasia is
disturbed, L1 expression tends to decline probably, as
Hilfirch pointed,7 because of the transcriptional and ge-
netic alterations within the epithelium. Morphologically
changed cells can run away from the immune system
since the L1 is one of the main targets for cell mediated
immune defence and proceed to malignant transforma-
tion. In present study statistically significant association
between negative L1 and cytological impairment of le-
sion during the time was demonstrated.
The result of p16 staining seems to be even more im-
portant for estimating progression of cervical lesions. In
cervical precancerous and cancerous lesion high level of
overexpressed p16 was found, suggesting it as a specific
biomarker for cells with expression of HPV oncogenes, as
many studies confirmed18,19. During the last decade, the
expression pattern of p16 in dysplastic squamous cells
has been extensively investigated. In general the propor-
tion of p16 positive cases is closely associated with the se-
verity of cytologic diagnoses. Relatively low proportion of
positivity (18% to 27%) was found in normal cervical
smears20,21. Positive staining can be found in metaplastic
cells because of their unfinished maturation, endosalpin-
giosis, or fallopian tube epithelium. A wide range of stud-
ies indicate that p16 is highly expressed in HSIL as well
in squamous cell carcinomas and not only that but its
positivity may achieve an interobserver reproducibility
in cytological as well as in a histological specimens20,22,23.
In present study overall positivity for p16 was 69.7%,
showing mainly unchanged or impairment of the cytolog-
ical finding during the time, and regression in only three
(4.5%) cases. The expression pattern results may be sum-
marised in four categories as was shown in Table 3. In
the groups with double positive (p16 +/L1+) result and
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positive p16 and negative L1 (p16+/L1–) result, impair-
ment of cytological finding was detected, so these pattern
may be defined as »high-risk«, especially p16+/L1– pat-
tern, and should be followed by cytology or by colposcopy
and accordingly biopsy. Groups with p16 negative and L1
positive (p16–/L1+), or double negative (p16–/L1–) result
may be defined as the »low-risk« pattern. In the double
negative pattern was found that cytological finding im-
proved in eight out of nine such lesions. Repeated analy-
sis showed that probably because of the inflammatory or
degenerative changes, smears were mistakenly evaluated
as dysplastic. The p16–/L1+ pattern means that virus is
present in the epithelial cells in productive phase, pro-
ducing new virions and all p16–/L1+ findings were un-
changed or improved during the time of follow up, and no
impairment of cytological finding was detected, which in-
dicate that only regular cytology control is needed.
In conclusion, the combination of these two biomar-
kers along with the cytology could be useful for identifi-
cation of the patients at risk of lesion progression and
can contribute to better understanding of biological po-
tentiality of cervical lesions. Present two year prospec-
tive study indicated association between p16+/L1– im-
munocytochemistry and impairment of cytological find-
ing. Further, larger studies are needed to confirm the
need of detecting HPV L1 and p16 as well as other
biomarkers in laboratory and clinical routine for better
planning of the clinical management of patients with cer-
vical abnormalities.
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PROCJENA KLINI^KOG ISHODA HPV-OM INDUCIRANIH LEZIJA VRATA MATERNICE
DETEKCIJOM KAPSIDNOG PROTEINA L1 I STANI^NOG PROTEINA p16INK4a
S A @ E T A K
Svrha istra`ivanja bila je istra`iti mogu}nost predvi|anja klini~kog ishoda lezije vrata maternice uz pomo} imuno-
lo{kih testova provedenim na obriscima vrata maternice. Tijekom dvogodi{njeg razdoblja istra`ivanja prikupljani su
obrisci u 81 pacijentica. Sve su testirane na humane papiloma viruse pomo}u Amplycor HPV testa.U 66 pacijentica je
detektiran HPV visokog rizika (hrHPV) i intraepitelna lezija, pa su obrisci vrata maternice u tih pacijentica ponavljani
svakih {est mjeseci. Ostale su bile hrHPV negativne pacijentice s normalnim obriscima koji su upotrijebljeni kao ne-
gativna kontrola u imunolo{kim testovima s HPV L1 i p16INK4a protutijelima. Rezultati p16INK4a bojanja u 66 hrHPV
pozitivnih pacijentica pokazali su pogor{anje cervikalne lezije u 22 (33,3%) a nepromijenjen citolo{ki nalaz u 21 (31,9%)
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pacijentice, dok je pobolj{an citolo{ki nalaz opa`en u samo tri (4,5%) p16INK4a pozitivne pacijentice. Naprotiv, pogor{a-
nje citolo{kog nalaza nije vi|eno u p16INK4a negativnih pacijentica, dok je u 17 od 20 pacijentica iz te grupe nalaz bio
pobolj{an ili se normalizirao (p<0,01). Korelacija izme|u L1/p16 uzorka i citolo{kog nalaza pokazala je da je u samo
L1–/p16+ cervikalnih lezija detektirano pogor{anje citolo{kog nalaza u razdoblju istra`ivanja. U L1+/p16+ skupini
citolo{ki nalaz nije se mijenjao za vrijeme pra}enja u svih 11 pacijentica, dok je u ve}ine pacijentica (9/11) iz L1+/p16–
grupe do{lo do sni`avanja stupnja lezije ili normalizacije Papa testa. Upotreba p16INK4a i HPV L1 markera mo`e biti
korisna u procjeni biolo{kog potencijala i klini~kog ishoda cervikalnih lezija.
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